title: Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma.
abstract: The aims of this study were to evaluate the efficacy of an empirically determined "fixed" high ablative dose of radioiodine ((131)I) therapy and to determine the utility of ultrasonography (US) in dose determination. A retrospective analysis was performed of 242 thyroid cancer cases treated with "fixed" high-dose (131)I for ablation of thyroid remnants without a pre-ablative (131)I diagnostic scintigraphy or radioiodine uptake study. Treatment doses ranged from 1850 MBq (50 mCi) to 7.4 GBq (200 mCi). The selection of the treatment dose was based on the surgical and pathological findings as well as the remnant thyroid volume calculated by US. A successful ablation was defined as the absence of activity in the thyroid bed on subsequent imaging studies. Successful ablation was obtained in 218 of the 242 patients (90%). In 162 of the 218 patients (74.3%), successful ablation was achieved after a single (131)I treatment. The remnant thyroid volume calculated by US was significantly different (P=0.04) between those who were successfully ablated and those who were not. The total (131)I dose needed for successful ablation was significantly higher in males (P=0.003). Patients with higher post-operative thyroglobulin (Tgb) levels and patients with a higher stage of disease required higher doses (P=0.036 and P=0.021 respectively). Serum Tgb levels were under 10 ng.ml(-1) in 220 of the 242 patients (90%) following radioiodine ablation while not receiving L-thyroxine suppression. Nineteen patients (7.8%) showed metastases on post-therapy scan and successful treatment was achieved in 11 of 19 (57.8%). Four of the 19 patients with distant metastases (revealed on post-treatment scan) were found to have been given a treatment dose of less than 200 mCi based on the proposed empirical approach. These results indicate that "fixed" high-dose (131)I treatment is clinically feasible with an acceptable dose underestimation rate, and the utilization of US in the determination of the thyroid remnant volume provides more accurate and reproducible results.
authors.affiliation: Department of Nuclear Medicine, Gülhane Military Medical Academy and Medical Faculty, 06018, Etlik, Ankara, Turkey.
authors.forename: N
authors.initials: N
authors.lastname: Arslan
authors.forename: S
authors.initials: S
authors.lastname: Ilgan
authors.forename: M
authors.initials: M
authors.lastname: Serdengecti
authors.forename: M A
authors.initials: MA
authors.lastname: Ozguven
authors.forename: H
authors.initials: H
authors.lastname: Bayhan
authors.forename: K
authors.initials: K
authors.lastname: Okuyucu
authors.forename: S A
authors.initials: SA
authors.lastname: Gulec
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D013965:Thyroidectomy; D014463:Ultrasonography
chemical_list: D007457:Iodine Radioisotopes; D013954:Thyroglobulin